- Jun 23, 2022
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
- Jun 21, 2022
National Cancer Institute: Clinical Trials Information for Patients and Caregivers
- Jun 11, 2022
Patient Education: Dexamethasaone (Decadron) and other Steroids
- Jun 10, 2022
NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM
- Jun 10, 2022
NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
- Jun 10, 2022
Patient Education: Selinexor (Xpovio) - XPO1 inhibitor
- Jun 10, 2022
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T
- Jun 10, 2022
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
- Jun 5, 2022
NCT05405166: Phase 3: SC Versus IV Isatuximab in Combination With Pomalidomide & Dexamethasone RRMM
- Jun 4, 2022
#ASCO22 Myeloma Abstracts - 2022 ASCO Annual Meeting: JUNE 3-7, 2022 Chicago, IL
- May 31, 2022
#EHA2022 - Myeloma Abstracts - EHA2022 Congress: June 9 - 12, 2022 - Vienna, Austria
- May 31, 2022
Dana-Farber's 2022 Multiple Myeloma Patient Symposium - Update on Multiple Myeloma Treatment